{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:51:39Z","timestamp":1791550299128,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Treatment with combined oral contraceptives (COC) is associated with an increased risk of venous thromboembolism. Several changes of coagulant and anticoagulant factors induced by ethinyloestradiol during treatment with COC, have been demonstrated. Thrombin generation is a global test measuring both coagulant and anticoagulant factors, but the effect of COC on individuals starting COC, has not been examined before on the new equipment, ST Genesia. The aim of this project was to examine the effect of COC on thrombin generation on ST Genesia, in individuals before and after starting COC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-four female participants between 15 and 34 years of age, who were about to start treatment with ethinylestradiol\/levonorgestrel-containing COC, were included in the study. Two blood samples were drawn from each of the study subjects, a baseline sample immediately before first COC dose, and a follow-up blood sample approximately 3\u20134 months after COC start. Standard biochemical analyses as well as standard and special coagulation analyses including thrombin generation on ST Genesia, were performed in all samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thrombin generation, i.e., endogenous thrombin generation (ETP) and peak increased considerably after COC start, whereas time-to-peak was shortened. Thrombin-antithrombin complexes (TAT), prothrombin fragments (F1\u2009+\u20092) and sex hormone binding globulin (SHBG) increased, and the coagulation inhibitors tissue factor pathway inhibitor (TFPI), protein S activity and antithrombin decreased slightly after COC start.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Although the coagulation factors only changed modestly, the global test thrombin generation performed on ST Genesia showed a considerable change after start of COC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12959-025-00713-z","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T10:26:39Z","timestamp":1744107999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of combined oral contraceptives on thrombin generation assessed on ST Genesia\u2013 a paired clinical study"],"prefix":"10.1186","volume":"23","author":[{"given":"Jesper","family":"Strandberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Lise","family":"Gade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Nybo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Nikolaj Laust","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Risom","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"713_CR1","unstructured":"United, Nations. D.o.E.a.S.A., Population Division (2019)., Contraceptive Use by Method 2019: Data Booklet (ST\/ESA\/SER.A\/435). 2019."},{"key":"713_CR2","unstructured":"Allen R. Combined estrogen-progestin oral contraceptives: Patient selection, counselling, and use. Courtney A Schreiber, editor UpToDate. Last updated: April 22, 2024. Retrieved: January 24, 2025. 2024."},{"issue":"8","key":"713_CR3","doi-asserted-by":"crossref","first-page":"e13628","DOI":"10.5812\/ircmj.13628","volume":"16","author":"M Shahnazi","year":"2014","unstructured":"Shahnazi M, et al. A comparison of second and third generations combined oral contraceptive pills\u2019 effect on mood. Iran Red Crescent Med J. 2014;16(8):e13628.","journal-title":"Iran Red Crescent Med J"},{"issue":"2","key":"713_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2016.07.007","volume":"95","author":"FZ Stanczyk","year":"2017","unstructured":"Stanczyk FZ, Mathews BW, Cortessis VK. Does the type of progestin influence the production of clotting factors? Contraception. 2017;95(2):113\u20136.","journal-title":"Contraception"},{"key":"713_CR5","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","volume":"339","author":"A van Hylckama Vlieg","year":"2009","unstructured":"van Hylckama Vlieg A, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.","journal-title":"BMJ"},{"key":"713_CR6","doi-asserted-by":"crossref","first-page":"1428597","DOI":"10.3389\/fendo.2024.1428597","volume":"15","author":"J Douxfils","year":"2024","unstructured":"Douxfils J, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1428597.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"713_CR7","doi-asserted-by":"crossref","first-page":"100266","DOI":"10.1016\/j.xagr.2023.100266","volume":"3","author":"JM Foidart","year":"2023","unstructured":"Foidart JM, et al. The benefits of estetrol addition to Drospirenone for contraception. AJOG Glob Rep. 2023;3(4):100266.","journal-title":"AJOG Glob Rep"},{"key":"713_CR8","doi-asserted-by":"crossref","unstructured":"Fruzzetti F et al. Estetrol: A new choice for contraception. J Clin Med, 2021. 10(23).","DOI":"10.3390\/jcm10235625"},{"issue":"10","key":"713_CR9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40265-022-01738-8","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A, Syed YY. Estetrol\/Drospirenone: A review in oral contraception. Drugs. 2022;82(10):1117\u201325.","journal-title":"Drugs"},{"issue":"1","key":"713_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.fertnstert.2016.09.027","volume":"107","author":"PC Medicine","year":"2017","unstructured":"Medicine PC..o.t.A.S.f.R., Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107(1):43\u201351.","journal-title":"Fertil Steril"},{"issue":"1","key":"713_CR11","first-page":"1","volume":"2","author":"A Baratloo","year":"2014","unstructured":"Baratloo A, et al. The risk of venous thromboembolism with different generation of oral contraceptives; a systematic review and Meta-Analysis. Emerg (Tehran). 2014;2(1):1\u201311.","journal-title":"Emerg (Tehran)"},{"issue":"1","key":"713_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"JA Heit","year":"2016","unstructured":"Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3\u201314.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"713_CR13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","volume":"44","author":"M Cushman","year":"2007","unstructured":"Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62\u20139.","journal-title":"Semin Hematol"},{"issue":"10","key":"713_CR14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2010.03986.x","volume":"8","author":"MJ Engbers","year":"2010","unstructured":"Engbers MJ, van Hylckama A, Vlieg, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8(10):2105\u201312.","journal-title":"J Thromb Haemost"},{"key":"713_CR15","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","volume":"343","author":"\u00d8 Lidegaard","year":"2011","unstructured":"Lidegaard \u00d8, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.","journal-title":"BMJ"},{"key":"713_CR16","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","volume":"339","author":"\u00d8 Lidegaard","year":"2009","unstructured":"Lidegaard \u00d8, et al. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ. 2009;339:b2890.","journal-title":"BMJ"},{"issue":"4 Pt 2","key":"713_CR17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9378(87)80129-1","volume":"157","author":"J Bonnar","year":"1987","unstructured":"Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 1987;157(4 Pt 2):1042\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"713_CR18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1365-2141.2001.02853.x","volume":"113","author":"IJ Mackie","year":"2001","unstructured":"Mackie IJ, et al. Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. Br J Haematol. 2001;113(4):898\u2013904.","journal-title":"Br J Haematol"},{"key":"713_CR19","doi-asserted-by":"crossref","unstructured":"Trenor CC 3, et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347\u201357.","DOI":"10.1542\/peds.2010-2221"},{"issue":"3","key":"713_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0950-3552(97)80027-2","volume":"11","author":"LA Norris","year":"1997","unstructured":"Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pill. Baillieres Clin Obstet Gynaecol. 1997;11(3):545\u201364.","journal-title":"Baillieres Clin Obstet Gynaecol"},{"issue":"3","key":"713_CR21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jth.12484","volume":"12","author":"HN Holmegard","year":"2014","unstructured":"Holmegard HN, et al. Endogenous sex hormones and risk of venous thromboembolism in women and men. J Thromb Haemost. 2014;12(3):297\u2013305.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"713_CR22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1160\/TH12-10-0771","volume":"109","author":"M Raps","year":"2013","unstructured":"Raps M, et al. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost. 2013;109(4):606\u201313.","journal-title":"Thromb Haemost"},{"issue":"6","key":"713_CR23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","volume":"98","author":"SN Tchaikovski","year":"2007","unstructured":"Tchaikovski SN, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost. 2007;98(6):1350\u20136.","journal-title":"Thromb Haemost"},{"issue":"5","key":"713_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.contraception.2017.01.001","volume":"95","author":"CL Westhoff","year":"2017","unstructured":"Westhoff CL, et al. Endogenous thrombin potential changes during the first cycle of oral contraceptive use. Contraception. 2017;95(5):456\u201363.","journal-title":"Contraception"},{"issue":"10","key":"713_CR25","doi-asserted-by":"crossref","first-page":"e0206376","DOI":"10.1371\/journal.pone.0206376","volume":"13","author":"ABO Mohamed","year":"2018","unstructured":"Mohamed ABO, et al. The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index. PLoS ONE. 2018;13(10):e0206376.","journal-title":"PLoS ONE"},{"issue":"1","key":"713_CR26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2141.1999.01302.x","volume":"105","author":"J Curvers","year":"1999","unstructured":"Curvers J, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105(1):88\u201394.","journal-title":"Br J Haematol"},{"issue":"1","key":"713_CR27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/1354750X.2016.1204010","volume":"22","author":"J Hugon-Rodin","year":"2017","unstructured":"Hugon-Rodin J, et al. Sex hormone-binding Globulin and thrombin generation in women using hormonal contraception. Biomarkers. 2017;22(1):81\u20135.","journal-title":"Biomarkers"},{"issue":"1","key":"713_CR28","doi-asserted-by":"crossref","first-page":"e12654","DOI":"10.1002\/rth2.12654","volume":"6","author":"SR Kristensen","year":"2022","unstructured":"Kristensen SR, Nybo J, Pedersen S. Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: assessment of analytical and between-subject variation. Res Pract Thromb Haemost. 2022;6(1):e12654.","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"713_CR29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ajh.24064","volume":"90","author":"A Zia","year":"2015","unstructured":"Zia A, et al. Hypercoagulability in adolescent girls on oral contraceptives-global coagulation profile and Estrogen receptor polymorphisms. Am J Hematol. 2015;90(8):725\u201331.","journal-title":"Am J Hematol"},{"issue":"3","key":"713_CR30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1538-7836.2011.04610.x","volume":"10","author":"R Lacroix","year":"2012","unstructured":"Lacroix R, et al. Impact of pre-analytical parameters on the measurement of Circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012;10(3):437\u201346.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"713_CR31","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1515\/cclm-2016-0793","volume":"54","author":"J Henny","year":"2016","unstructured":"Henny J, et al. Recommendation for the review of biological reference intervals in medical laboratories. Clin Chem Lab Med. 2016;54(12):1893\u2013900.","journal-title":"Clin Chem Lab Med"},{"key":"713_CR32","doi-asserted-by":"crossref","first-page":"12339","DOI":"10.3389\/bjbs.2024.12339","volume":"81","author":"NE Timbrell","year":"2024","unstructured":"Timbrell NE. The role and limitations of the reference interval within clinical chemistry and its reliability for disease detection. Br J Biomed Sci. 2024;81:12339.","journal-title":"Br J Biomed Sci"},{"issue":"4","key":"713_CR33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MBC.0000000000001198","volume":"34","author":"A Arafat","year":"2023","unstructured":"Arafat A, et al. Role of tissue factor pathway inhibitor in hormone-induced venous thromboembolism. Blood Coagul Fibrinolysis. 2023;34(4):233\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"713_CR34","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.metabol.2015.06.011","volume":"64","author":"D Glintborg","year":"2015","unstructured":"Glintborg D, et al. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of Metformin and oral contraceptives. Metabolism. 2015;64(10):1272\u20138.","journal-title":"Metabolism"},{"issue":"3","key":"713_CR35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12318","volume":"4","author":"MG Zermatten","year":"2020","unstructured":"Zermatten MG, et al. Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report. Res Pract Thromb Haemost. 2020;4(3):429\u201332.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"713_CR36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/clinem\/dgac511","volume":"108","author":"L Morimont","year":"2022","unstructured":"Morimont L, et al. Low thrombin generation in users of a contraceptive containing estetrol and Drospirenone. J Clin Endocrinol Metab. 2022;108(1):135\u201343.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"713_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00016348409156274","volume":"63","author":"GH Weenink","year":"1984","unstructured":"Weenink GH, et al. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand. 1984;63(1):57\u201361.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"713_CR38","doi-asserted-by":"crossref","unstructured":"Burkman RT et al. Oral contraceptives and antithrombin III: variations by dosage and ABO blood group. Am J Obstet Gynecol, 1991. 164(6 Pt 1): pp. 1453-8; discussion 1458-60.","DOI":"10.1016\/0002-9378(91)91424-U"},{"issue":"2","key":"713_CR39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7836.2008.02863.x","volume":"6","author":"HA van Vliet","year":"2008","unstructured":"van Vliet HA, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost. 2008;6(2):346\u201351.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"713_CR40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/ATVBAHA.117.309919","volume":"38","author":"P Tanratana","year":"2018","unstructured":"Tanratana P, et al. Elevated plasma factor IXa activity in premenopausal women on hormonal contraception. Arterioscler Thromb Vasc Biol. 2018;38(1):266\u201374.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"713_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<175::AID-AJH1>3.0.CO;2-X","volume":"60","author":"GM Harris","year":"1999","unstructured":"Harris GM, et al. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol. 1999;60(3):175\u201380.","journal-title":"Am J Hematol"},{"issue":"1","key":"713_CR42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","volume":"126","author":"SN Tchaikovski","year":"2010","unstructured":"Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010;126(1):5\u201311.","journal-title":"Thromb Res"},{"issue":"1","key":"713_CR43","first-page":"4","volume":"84","author":"S Middeldorp","year":"2000","unstructured":"Middeldorp S, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000;84(1):4\u20138.","journal-title":"Thromb Haemost"},{"issue":"1","key":"713_CR44","first-page":"9","volume":"84","author":"JC Meijers","year":"2000","unstructured":"Meijers JC, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 2000;84(1):9\u201314.","journal-title":"Thromb Haemost"},{"issue":"1","key":"713_CR45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","volume":"84","author":"G Tans","year":"2000","unstructured":"Tans G, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84(1):15\u201321.","journal-title":"Thromb Haemost"},{"issue":"1","key":"713_CR46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1743-6109.2005.00198.x","volume":"3","author":"C Panzer","year":"2006","unstructured":"Panzer C, et al. Impact of oral contraceptives on sex hormone-binding Globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med. 2006;3(1):104\u201313.","journal-title":"J Sex Med"},{"issue":"1","key":"713_CR47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/humupd\/dmt038","volume":"20","author":"Y Zimmerman","year":"2014","unstructured":"Zimmerman Y, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76\u2013105.","journal-title":"Hum Reprod Update"},{"issue":"2","key":"713_CR48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","volume":"20","author":"HA van Vliet","year":"2005","unstructured":"van Vliet HA, et al. Association between sex hormone-binding Globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod. 2005;20(2):563\u20138.","journal-title":"Hum Reprod"},{"issue":"6","key":"713_CR49","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","volume":"10","author":"M Raps","year":"2012","unstructured":"Raps M, et al. Sex hormone-binding Globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012;10(6):992\u20137.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"713_CR50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.contraception.2010.04.002","volume":"82","author":"V De Leo","year":"2010","unstructured":"De Leo V, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82(3):276\u201380.","journal-title":"Contraception"},{"issue":"1","key":"713_CR51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.contraception.2007.04.002","volume":"76","author":"T Greco","year":"2007","unstructured":"Greco T, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of Ethinyl estradiol. Contraception. 2007;76(1):8\u201317.","journal-title":"Contraception"},{"issue":"6","key":"713_CR52","first-page":"482","volume":"81","author":"V Odlind","year":"2002","unstructured":"Odlind V, et al. Can changes in sex hormone binding Globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002;81(6):482\u201390.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"713_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MBC.0000000000000784","volume":"30","author":"AL Eilertsen","year":"2019","unstructured":"Eilertsen AL, et al. Relationship between sex hormone binding Globulin and blood coagulation in women on postmenopausal hormone treatment. Blood Coagul Fibrinolysis. 2019;30(1):17\u201323.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"713_CR54","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/jth.13170","volume":"13","author":"H van Vlieg","year":"2015","unstructured":"van Vlieg H, A. and, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply. J Thromb Haemost. 2015;13(12):2286\u20137.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"713_CR55","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1538-7836.2009.03561.x","volume":"7","author":"PL Lutsey","year":"2009","unstructured":"Lutsey PL, et al. Peak thrombin generation and subsequent venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE) study. J Thromb Haemost. 2009;7(10):1639\u201348.","journal-title":"J Thromb Haemost"},{"key":"713_CR56","doi-asserted-by":"crossref","unstructured":"Vrotniakaite-Bajerciene K et al. Thrombin generation is associated with venous thromboembolism recurrence, but not with major bleeding and death in the elderly: A prospective multicenter cohort study. J Clin Med, 2023. 12(18).","DOI":"10.3390\/jcm12186050"},{"key":"713_CR57","doi-asserted-by":"crossref","first-page":"769187","DOI":"10.3389\/fendo.2021.769187","volume":"12","author":"L Morimont","year":"2021","unstructured":"Morimont L, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021;12:769187.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"713_CR58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.thromres.2023.07.007","volume":"229","author":"SR Kristensen","year":"2023","unstructured":"Kristensen SR, et al. Estimation of the preanalytical activation of the contact system in coagulation tubes. Thromb Res. 2023;229:149\u201351.","journal-title":"Thromb Res"},{"issue":"5","key":"713_CR59","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.thromres.2014.09.008","volume":"134","author":"SN Tchaikovski","year":"2014","unstructured":"Tchaikovski SN, et al. Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives. Thromb Res. 2014;134(5):1032\u20137.","journal-title":"Thromb Res"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00713-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00713-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:59:20Z","timestamp":1744217960000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00713-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00713-z","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional Danish research ethics committee (N-20200098 ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}